# ANNOUNCEMENT LETTER

PrECISE: Personalized Engine for Cancer Integrative Study and Evaluation

PrECISE: Personalized Engine for Cancer Integrative Study and Evaluation

PrECISE, a Pan-European and American cooperative research project has officially started on 1st January 2016 with a set duration of 36 months. PrECISE aims to improve patient risk-stratification and treatment in prostate cancer by developing new computational approaches to exploit next generation molecular data. The expected outcome is the development of a predictive computational technology that can exploit molecular and clinical data to improve the understanding of disease mechanism and to inform clinicians about optimized treatment strategies. The main objectives of PrECISE are to **develop new approaches to exploit molecular data**, to **distinguish the indolent tumours from the minority lethal ones and to provide treatment recommendations**. A successful stratification of primary prostate cancer patients into clinically significant and insignificant disease leads to minimizing unsuccessful surgeries and therefore lowers medical costs. Moreover, it enables more personalized, rationally chosen treatments for patients.

| Develop comprehensive computational technology | Use PrECISE to build personalized disease models for each patient | Use PrECISE to suggest chemotherapy drugs and targeted therapies for each patient | Develop a deployable, easy to use software tool |

Challenges faced by the consortium include integrating multiple types of molecular data and accounting for the high intra- and inter-tumour heterogeneity in human cancers.

The **PrECISE** consortium is well-positioned to achieve its objectives by bringing together a team of two research institutes, two research oriented SME´s, four universities and one leading industrial company from six different countries to form a complete chain stretching from basic research and service design, via applied research, up to end-user oriented service providers. The PrECISE project is supported by the following partners who provide well-experienced teams in research and management:

- TECHNIKON Forschungs- und Planungsgesellschaft mbH, Austria
- IBM research GmbH, Switzerland
- Technische Universität Darmstadt, Germany
- RWTH Aachen University Hospital Aachen, Germany
- Eidgenössische Technische Hochschule Zürich, Switzerland
- Universität Zürich, Switzerland
- Baylor College of Medicine – Houston, Texas, United States
- Institut Curie, France
- AstridBio Technologies Kft, Hungary

For more information visit http://www.precise-project.eu [coming soon]

Contact information:

Project coordinator:	**Technical leader:**	**Scientific leader:**
Dr.-Ing. Klaus-Michael Koch	Dr. María Rodríguez Martínez	Prof. Julio Saez-Rodriguez
TECHNIKON Forschungs- und Planungsgesellschaft mbH	IBM Zurich	RWTH Aachen University Hospital Joint Research Center for Computational Biomedicine
Burgplatz 3a	Saeumerstrasse 4	Wendlingsweg 2, MTI2
9500 Villach	8803 Rueschlikon	52074 Aachen
Austria	Switzerland	Germany
Email: coordination@precise-project.eu	Email: MRM@zurich.ibm.com	Email: saezrodriguez@combine.rwth-aachen.de

The project receives funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement n° 668858.